Compare ZDGE & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDGE | PRPO |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | 55 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 40.1M |
| IPO Year | 2016 | 2000 |
| Metric | ZDGE | PRPO |
|---|---|---|
| Price | $3.00 | $25.89 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 192.8K | 23.9K |
| Earning Date | 06-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | 73.85 | ★ 92.15 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,398,000.00 | $24,049,000.00 |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $5.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $2.21 | $13.02 |
| 52 Week High | $4.70 | $33.63 |
| Indicator | ZDGE | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 63.85 |
| Support Level | $2.87 | $25.95 |
| Resistance Level | $3.16 | $29.02 |
| Average True Range (ATR) | 0.13 | 1.74 |
| MACD | -0.01 | 0.46 |
| Stochastic Oscillator | 21.05 | 81.84 |
Zedge Inc builds digital marketplaces and competitive games centered on content that people use for self-expression. Its products include the Zedge App, a freemium digital content marketplace offering mobile wallpapers, video wallpapers, ringtones, and notification sounds, along with pAInt, a generative AI wallpaper and ringtone maker, GuruShots, a skill-based photo challenge game, and Emojipedia, a trusted source for emoji information. The Zedge App is available on Google Play and the App Store. The company operates two segments: Zedge Marketplace and GuruShots, with the majority of revenue generated from the Zedge Marketplace.
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.